Core Insights - Paysign's patient affordability business was the primary driver of growth in 2025, with segment revenue increasing by 168% year-over-year to $33.9 million from $12.7 million, and processed claims rising approximately 79% [1][6] Financial Performance - For the full year 2025, Paysign reported a revenue increase of 40.5% to $82.0 million, with net income rising 98% to $7.6 million and adjusted EBITDA increasing 107% to $19.9 million [3][7] - Operating expenses totaled $41.4 million, up 32.6%, which was below the revenue growth rate, while gross margin improved to 59.4% from 55.1% a year earlier [2] - Operating margin rose to 9% from 1.7% in the prior year, attributed to scalability in the cost structure as the patient affordability business grew [2][3] Business Segments - The patient affordability platform delivered nearly $1 billion in assistance to over 840,000 individuals in 2025, with dynamic rules saving clients over $325 million [6][7] - The plasma donor compensation business generated $45.6 million in revenue for 2025, reflecting a 4% increase from $43.9 million in 2024, supported by the addition of 115 net plasma centers [11] Future Outlook - Paysign expects 2026 revenue to be between $106.5 million and $110.5 million, representing 30% to 35% growth, with adjusted EBITDA projected at $30 million to $33 million [5][16] - The company anticipates net income for 2026 to be between $13 million and $16 million, or $0.21 to $0.26 per diluted share [17] Strategic Initiatives - Paysign added 55 programs in 2025, ending the year with 131 active programs across more than 70 patient affordability clients, including relationships with six of the top 10 U.S. pharmaceutical manufacturers [8][6] - The company is awaiting FDA 510(k) review for its donor management system and expects to hear back within the next 60 days [13] Market Position - The company maintains a strong balance sheet, exiting 2025 with $21.1 million in cash and no bank debt, indicating robust financial health [15]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported sales of EUR 12.4 billion, representing a 7% increase compared to the previous year [4] - Business EPS reached EUR 2.91, reflecting a robust growth of EUR 0.19 or 13% compared to Q3 2024 [15] - The gross margin increased by 2.3 percentage points this quarter, driven by an improved product mix and productivity gains [13] Business Line Data and Key Metrics Changes - Pharmaceutical sales grew by 7% at constant exchange rates, primarily driven by immunology and recent launches [13] - New product launches contributed EUR 1.8 billion in sales this quarter, accounting for 15% of total sales [6] - Dupixent sales reached EUR 4 billion for the first time, with a 26% growth this quarter [7][15] Market Data and Key Metrics Changes - Vaccine sales were EUR 3.4 billion, reflecting a decrease due to competitive price pressure and lower flu immunization rates in the U.S. [8] - Outside the U.S., Dupixent sales grew by 21%, exceeding EUR 1 billion in the quarter [8] - Beyfortus sales increased by 20% this quarter, now available in 40 countries [9] Company Strategy and Development Direction - The company aims to improve access to treatments and lower prices for patients, as demonstrated by the expansion of its patient affordability program for insulins [5][11] - The focus remains on innovation in respiratory vaccines and expanding the commercial portfolio with new product launches [10][11] - The company is committed to maintaining a balanced capital allocation policy, focusing on organic growth, selective acquisitions, and progressive dividends [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business outlook for the remainder of the year and reiterated full-year sales guidance [4] - The company anticipates continued growth momentum, with expectations for high single-digit sales growth and low double-digit business EPS growth at constant exchange rates for the full year [15][16] - Management acknowledged challenges in the vaccine segment but remains committed to innovation and improving patient access [10][11] Other Important Information - The company has achieved a milestone of treating 1 million patients for non-communicable diseases across low and middle-income countries since 2021 [11] - The company has completed acquisitions of Drensbios DR0201, Vigil Neuroscience, and Blueprint, with associated costs factored into guidance [15] Q&A Session Summary Question: Update on Poly-SPMS regulatory debate and confidence in resolving FDA questions - Management confirmed ongoing conversations with the FDA and submitted data sets, looking forward to the PDUFA date of December 28 [32] Question: Update on U.S. policy conversations - Management stated that dialogues with the U.S. government have been ongoing and focused on demonstrating the value the company can bring [38] Question: Q4 ordering trends for Beyfortus - Management confirmed expectations for Q4 performance to be similar to Q3, with a focus on increasing vaccination coverage rates in the U.S. [42][44] Question: Insights on Dupixent's COPD development and gross to net dynamics - Management highlighted strong growth in COPD and indicated that gross to net dynamics are monitored and included in long-term guidance [81] Question: Timing dynamics around riliprubart and other programs under review - Management indicated that timelines for riliprubart are being updated and that data from various studies will be presented at relevant scientific congresses [62] Question: Potential for product acquisitions and vaccine trends - Management acknowledged the success of Dupixent and indicated a cautious approach to M&A, while also addressing concerns about vaccine fatigue [90]

Financial Data and Key Metrics Changes - Revenue grew 41% year over year to $18.6 million, up from $13.2 million in Q1 of last year [5] - Net income surged to $2.59 million, a 737% increase over Q1 2024 [5] - Adjusted EBITDA jumped 193% to $4.9 million, with gross margin expanding over 10 points to 62.9% [5][6] Business Line Data and Key Metrics Changes - Patient Affordability business revenues rose 261% year over year to $8.6 million, with claims processed growing by more than 160% [6] - Plasma donor compensation revenue decreased 9.2% to $9.4 million, with revenue per plasma center declining to $6,517 [10][14] Market Data and Key Metrics Changes - The Patient Affordability segment accounted for 46.3% of quarterly revenues, a significant increase from 18.1% in the same period last year [15] - The company ended the quarter with 484 plasma centers, adding four new centers during the period [10][14] Company Strategy and Development Direction - The acquisition of Gamma Innovation is expected to enhance the tech stack and offer a full front-end engagement platform integrated with core payment solutions [11][12] - The company aims to unlock additional revenue streams and expand its total addressable market beyond the plasma sector into broader pharmaceutical and healthcare sectors [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory and commitment to delivering long-term value to shareholders [13] - The company expects patient affordability revenue to more than double again in 2025 based on current pipeline and results [8] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt [17] - Full-year gross profit margins are expected to be between 62% to 64%, reflecting stable margins in the plasma business and increased contributions from the higher-margin pharma patient affordability business [18] Q&A Session Summary - No questions were raised during the Q&A session [21]

Financial Data and Key Metrics Changes - Revenue grew 41% year over year to $18.6 million, up from $13.2 million in Q1 2024 [5][16] - Net income surged to $2.59 million, a 737% increase over Q1 2024 [5][16] - Adjusted EBITDA jumped 193% to $4.9 million, with gross margin expanding over 10 points to 62.9% [5][16] Business Line Data and Key Metrics Changes - Patient Affordability business revenues rose 261% year over year to $8.6 million, with claims processed growing by more than 160% [6][15] - Plasma donor compensation revenue decreased 9.2% to $9.4 million, with revenue per plasma center declining to $6,517 [9][14] Market Data and Key Metrics Changes - The Patient Affordability segment accounted for 46.3% of quarterly revenues, a significant increase from 18.1% in the same period last year [15] - The company added 14 new programs in the Patient Affordability business, totaling 90 active programs [6][15] Company Strategy and Development Direction - The company is investing in innovation, including the acquisition of Gamma Innovation to enhance its tech stack and expand its offerings in the plasma market [11][12] - The integrated model from the Gamma acquisition is expected to unlock additional revenue streams and strengthen competitive differentiation [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory and commitment to delivering long-term value to shareholders [13] - The company expects patient affordability revenue to more than double again in 2025 based on current pipeline trends [8] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt [17] - Full year gross profit margins are expected to be between 62% to 64% [19] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded without further inquiries [22]